Ipilimumab for Patients with Relapse after Allogeneic Transplantation

BACKGROUND: Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We hypothesized that immune checkpoint blockade established by targeting cytotoxic T-lymphocyte–associated protein 4 with ipilimumab co...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:N Engl J Med
Prif Awduron: Davids, Matthew S., Kim, Haesook T., Bachireddy, Pavan, Costello, Caitlin, Liguori, Rebecca, Savell, Alexandra, Lukez, Alexander P., Avigan, David, Chen, Yi-Bin, McSweeney, Peter, LeBoeuf, Nicole R., Rooney, Michael S., Bowden, Michaela, Zhou, Chensheng W., Granter, Scott R., Hornick, Jason L., Rodig, Scott J., Hirakawa, Masahiro, Severgnini, Mariano, Hodi, F. Stephen, Wu, Catherine J., Ho, Vincent T., Cutler, Corey, Koreth, John, Alyea, Edwin P., Antin, Joseph H., Armand, Philippe, Streicher, Howard, Ball, Edward D., Ritz, Jerome, Bashey, Asad, Soiffer, Robert J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5149459/
https://ncbi.nlm.nih.gov/pubmed/27410923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1601202
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg